Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium

被引:530
作者
Falzone, Luca [1 ]
Salomone, Salvatore [1 ,2 ]
Libra, Massimo [1 ,2 ]
机构
[1] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy
[2] Univ Catania, Res Ctr Prevent Diag & Treatment Canc PreDiCT, Catania, Italy
关键词
cancer; antineoplastic drugs; chemotherapy; targeted therapy; cell therapy; GROWTH-FACTOR RECEPTOR; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; PHASE-II TRIAL; ANTI-CD20; MONOCLONAL-ANTIBODY; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLANT ANTITUMOR AGENTS; QUALITY-OF-LIFE; TYROSINE KINASE; COMBINATION CHEMOTHERAPY;
D O I
10.3389/fphar.2018.01300
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The medical history of cancer began millennia ago. Historical findings of patients with cancer date back to ancient Egyptian and Greek civilizations, where this disease was predominantly treated with radical surgery and cautery that were often ineffective, leading to the death of patients. Over the centuries, important discoveries allowed to identify the biological and pathological features of tumors, without however contributing to the development of effective therapeutic approaches until the end of the 1800s, when the discovery of X-rays and their use for the treatment of tumors provided the first modern therapeutic approach in medical oncology. However, a real breakthrough took place after the Second World War, with the discovery of cytotoxic antitumor drugs and the birth of chemotherapy for the treatment of various hematological and solid tumors. Starting from this epochal turning point, there has been an exponential growth of studies concerning the use of new drugs for cancer treatment. The second fundamental breakthrough in the field of oncology and pharmacology took place at the beginning of the '80s, thanks to molecular and cellular biology studies that allowed the development of specific drugs for some molecular targets involved in neoplastic processes, giving rise to targeted therapy. Both chemotherapy and target therapy have significantly improved the survival and quality of life of cancer patients inducing sometimes complete tumor remission. Subsequently, at the turn of the third millennium, thanks to genetic engineering studies, there was a further advancement of clinical oncology and pharmacology with the introduction of monoclonal antibodies and immune checkpoint inhibitors for the treatment of advanced or metastatic tumors, for which no effective treatment was available before. Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment. Currently, several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, we will certainly assist to a new revolution in the field of medical oncology.
引用
收藏
页数:26
相关论文
共 282 条
  • [1] INHIBITORS OF POLYAMINE BIOSYNTHESIS .1. ALPHA-METHYL-(+/-)-ORNITHINE, AN INHIBITOR OF ORNITHINE DECARBOXYLASE
    ABDELMONEM, MM
    NEWTON, NE
    WEEKS, CE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1974, 17 (04) : 447 - 451
  • [2] EFFICACY OF ANTIBODIES TO EPIDERMAL GROWTH-FACTOR RECEPTOR AGAINST KB CARCINOMA INVITRO AND IN NUDE-MICE
    ABOUDPIRAK, E
    HURWITZ, E
    PIRAK, ME
    BELLOT, F
    SCHLESSINGER, J
    SELA, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (20) : 1605 - 1611
  • [3] Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors
    Adams, Val R.
    Leggas, Markos
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (07) : 1338 - 1353
  • [4] Al-Badr Abdullah A, 2016, Profiles Drug Subst Excip Relat Methodol, V41, P323, DOI 10.1016/bs.podrm.2015.12.002
  • [5] Amdahl J, 2016, ONCOL THER, V4, P239, DOI 10.1007/s40487-016-0030-2
  • [6] ANAFI M, 1993, BLOOD, V82, P3524
  • [7] Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223
    Anderson, Peter M.
    Subbiah, Vivek
    Rohren, Eric
    [J]. CURRENT ADVANCES IN OSTEOSARCOMA, 2014, 804 : 291 - 304
  • [8] [Anonymous], E SMITH PAPYRUS UPDA
  • [9] [Anonymous], IL GIORNALE ITAL RAD
  • [10] [Anonymous], 2016, EMA/CHMP/BWP/532517/2008